Dickler, M. N., Tolaney, S. M., Rugo, H. S., Cortés, J., Diéras, V., Patt, D., . . . Baselga, J. (2017). MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2− metastatic breast cancer. Clin Cancer Res.
Stile di citazione ChicagoDickler, Maura N., et al. "MONARCH 1, a Phase 2 Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, As a Single Agent, in Patients With Refractory HR+/HER2− Metastatic Breast Cancer." Clin Cancer Res 2017.
Citazione MLADickler, Maura N., et al. "MONARCH 1, a Phase 2 Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, As a Single Agent, in Patients With Refractory HR+/HER2− Metastatic Breast Cancer." Clin Cancer Res 2017.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.